Limbo, Adelaida S.

HRN: 22 34 42  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/17/2022
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
12/17/2022
12/26/2022
IV
1.5gm
Q6
Aspiration Pneumonia
Waiting Final Action 
12/17/2022
CLINDAMYCIN 150MG/ML, 4ML (AMP)
12/17/2022
12/23/2022
IV
600mg
Q8
Aspiration Pneumonia
Waiting Final Action 
12/20/2022
AZITHROMYCIN 500MG TABLET (TAB)
12/20/2022
12/24/2022
PO
500 Mg
OD
Cap
Waiting Final Action 
12/25/2022
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
12/25/2022
12/27/2022
IV
1.5g
Q6
CAP MR
Waiting Final Action 
12/30/2022
CO-AMOXICLAV 625MG (TAB)
12/30/2022
01/05/2023
ORAL
625mg
Bid
CAP HR COPD
Waiting Final Action 
02/24/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
02/24/2023
03/02/2023
IV
4.5g
Q6
CAP-HR
Waiting Final Action 
02/24/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
02/24/2023
03/02/2023
IV
500mg
Q8
CAP-HR
Waiting Final Action 
03/05/2023
CEFIXIME 200MG (CAP)
03/05/2023
03/12/2023
PO
200mg
BID
Cap Hr (step Down)
Waiting Final Action 
07/16/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
07/16/2023
07/22/2023
IVT
4.5g
Q6
CAP HR
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: